Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine.

Modern rheumatology

Uemura Y, Senju S, Fujii S, Iwai LK, Maenaka K, Tabata H, Kanai T, Chen YZ, Nishimura Y.
PMID: 24387206
Mod Rheumatol. 2003 Sep;13(3):205-14. doi: 10.3109/s10165-003-0225-x.

Abstract In humans, increased susceptibility to specific autoimmune diseases is closely associated with specific HLA-class II alleles. CD4(+) T cells that recognize short self-peptides in the context of HLA-class II molecules via their T cell receptor (TCR) are considered...

Cite
Uemura Y, Senju S, Fujii S, et al. Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine. Mod Rheumatol. 2003;13(3):205-14doi: 10.3109/s10165-003-0225-x.
Uemura, Y., Senju, S., Fujii, S., Iwai, L. K., Maenaka, K., Tabata, H., Kanai, T., Chen, Y. Z., & Nishimura, Y. (2003). Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine. Modern rheumatology, 13(3), 205-14. https://doi.org/10.3109/s10165-003-0225-x
Uemura, Yasushi, et al. "Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine." Modern rheumatology vol. 13,3 (2003): 205-14. doi: https://doi.org/10.3109/s10165-003-0225-x
Uemura Y, Senju S, Fujii S, Iwai LK, Maenaka K, Tabata H, Kanai T, Chen YZ, Nishimura Y. Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine. Mod Rheumatol. 2003 Sep;13(3):205-14. doi: 10.3109/s10165-003-0225-x. PMID: 24387206.
Copy Download .nbib Format: NLM
Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.

Oncoimmunology

van Luijn MM, Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA, Marieke van Ham S.
PMID: 22720245
Oncoimmunology. 2012 Mar 01;1(2):211-213. doi: 10.4161/onci.1.2.18100.

In this overview, we discuss the role of class II-associated invariant chain peptide (CLIP) in acute myeloid leukemia (AML), one of the few tumors expressing HLA class II. The clinical impact, function and regulation of CLIP expression on leukemic...

Cite
van Luijn MM, Chamuleau ME, Ossenkoppele GJ, et al. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology. 2012;1(2):211-213doi: 10.4161/onci.1.2.18100.
van Luijn, M. M., Chamuleau, M. E., Ossenkoppele, G. J., van de Loosdrecht, A. A., & Marieke van Ham, S. (2012). Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology, 1(2), 211-213. https://doi.org/10.4161/onci.1.2.18100
van Luijn, Marvin M, et al. "Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation." Oncoimmunology vol. 1,2 (2012): 211-213. doi: https://doi.org/10.4161/onci.1.2.18100
van Luijn MM, Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA, Marieke van Ham S. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology. 2012 Mar 01;1(2):211-213. doi: 10.4161/onci.1.2.18100. PMID: 22720245; PMCID: PMC3376995.
Copy Download .nbib Format: NLM
Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase.

Acta naturae

Starodubova ES, Isaguliants MG, Kuzmenko YV, Latanova AA, Krotova OA, Karpov VL.
PMID: 24772328
Acta Naturae. 2014 Jan;6(1):61-8.

Intracellular processing of the antigen encoded by a DNA vaccine is one of the key steps in generating an immune response. Immunization with DNA constructs targeted to the endosomal-lysosomal compartments and to the MHC class II pathway can elicit...

Cite
Starodubova ES, Isaguliants MG, Kuzmenko YV, et al. Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta Naturae. 2014;6(1):61-8
Starodubova, E. S., Isaguliants, M. G., Kuzmenko, Y. V., Latanova, A. A., Krotova, O. A., & Karpov, V. L. (2014). Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta naturae, 6(1), 61-8.
Starodubova, E S, et al. "Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase." Acta naturae vol. 6,1 (2014): 61-8.
Starodubova ES, Isaguliants MG, Kuzmenko YV, Latanova AA, Krotova OA, Karpov VL. Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta Naturae. 2014 Jan;6(1):61-8. PMID: 24772328; PMCID: PMC3999467.
Copy Download .nbib Format: NLM
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.

Oncoimmunology

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S.
PMID: 30723591
Oncoimmunology. 2019 Jan 11;8(3):1558663. doi: 10.1080/2162402X.2018.1558663. eCollection 2019.

Eradication of tumors by the immune system relies on the efficient activation of a T-cell response. For many years, the main focus of cancer immunotherapy has been on cytotoxic CD8 T-cell. However, stimulation of CD4 helper T cells is...

Cite
Mensali N, Grenov A, Pati NB, et al. Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. Oncoimmunology. 2019;8(3):1558663doi: 10.1080/2162402X.2018.1558663.
Mensali, N., Grenov, A., Pati, N. B., Dillard, P., Myhre, M. R., Gaudernack, G., Kvalheim, G., Inderberg, E. M., Bakke, O., & Wälchli, S. (2019). Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. Oncoimmunology, 8(3), 1558663. https://doi.org/10.1080/2162402X.2018.1558663
Mensali, Nadia, et al. "Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity." Oncoimmunology vol. 8,3 (2019): 1558663. doi: https://doi.org/10.1080/2162402X.2018.1558663
Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S. Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. Oncoimmunology. 2019 Jan 11;8(3):1558663. doi: 10.1080/2162402X.2018.1558663. eCollection 2019. PMID: 30723591; PMCID: PMC6350688.
Copy Download .nbib Format: NLM
Invariant Chain Complexes and Clusters as Platforms for MIF Signaling.

Cells

Lindner R.
PMID: 28208600
Cells. 2017 Feb 10;6(1). doi: 10.3390/cells6010006.

Invariant chain (Ii/CD74) has been identified as a surface receptor for migration inhibitory factor (MIF). Most cells that express Ii also synthesize major histocompatibility complex class II (MHC II) molecules, which depend on Ii as a chaperone and a...

Cite
Lindner R. Invariant Chain Complexes and Clusters as Platforms for MIF Signaling. Cells. 2017;6(1)doi: 10.3390/cells6010006.
Lindner, R. (2017). Invariant Chain Complexes and Clusters as Platforms for MIF Signaling. Cells, 6(1), . https://doi.org/10.3390/cells6010006
Lindner, Robert. "Invariant Chain Complexes and Clusters as Platforms for MIF Signaling." Cells vol. 6,1 (2017). doi: https://doi.org/10.3390/cells6010006
Lindner R. Invariant Chain Complexes and Clusters as Platforms for MIF Signaling. Cells. 2017 Feb 10;6(1). doi: 10.3390/cells6010006. PMID: 28208600; PMCID: PMC5371871.
Copy Download .nbib Format: NLM
The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.

Immunobiology

Antohe I, Tanasa MP, Dăscălescu A, Dănăilă C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Cianga P.
PMID: 33352400
Immunobiology. 2021 Jan;226(1):152049. doi: 10.1016/j.imbio.2020.152049. Epub 2020 Dec 03.

Acute Myeloid Leukaemia (AML) is a neoplasia characterised by rapid proliferation and an increased rate of relapses. The AML blasts display features of antigen-presenting cells (APC), and thus can directly modulate the anti-tumour T cell responses. The bone marrow...

Cite
Antohe I, Tanasa MP, Dăscălescu A, et al. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology. 2020;226(1):152049doi: 10.1016/j.imbio.2020.152049.
Antohe, I., Tanasa, M. P., Dăscălescu, A., Dănăilă, C., Titieanu, A., Zlei, M., Ivanov, I., Sireteanu, A., & Cianga, P. (2021). The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology, 226(1), 152049. https://doi.org/10.1016/j.imbio.2020.152049
Antohe, Ion, et al. "The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression." Immunobiology vol. 226,1 (2021): 152049. doi: https://doi.org/10.1016/j.imbio.2020.152049
Antohe I, Tanasa MP, Dăscălescu A, Dănăilă C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Cianga P. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology. 2021 Jan;226(1):152049. doi: 10.1016/j.imbio.2020.152049. Epub 2020 Dec 03. PMID: 33352400.
Copy Download .nbib Format: NLM
Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome.

Frontiers in immunology

Fortin JS, Cloutier M, Thibodeau J.
PMID: 24379812
Front Immunol. 2013 Dec 13;4:443. doi: 10.3389/fimmu.2013.00443.

The peptide repertoire (peptidome) associated with MHC class II molecules (MHCIIs) is influenced by the polymorphic nature of the peptide binding groove but also by cell-intrinsic factors. The invariant chain (Ii) chaperones MHCIIs, affecting their folding and trafficking. Recent...

Cite
Fortin JS, Cloutier M, Thibodeau J. Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome. Front Immunol. 2013;4:443doi: 10.3389/fimmu.2013.00443.
Fortin, J. S., Cloutier, M., & Thibodeau, J. (2013). Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome. Frontiers in immunology, 4443. https://doi.org/10.3389/fimmu.2013.00443
Fortin, Jean-Simon, et al. "Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome." Frontiers in immunology vol. 4 (2013): 443. doi: https://doi.org/10.3389/fimmu.2013.00443
Fortin JS, Cloutier M, Thibodeau J. Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome. Front Immunol. 2013 Dec 13;4:443. doi: 10.3389/fimmu.2013.00443. PMID: 24379812; PMCID: PMC3861868.
Copy Download .nbib Format: NLM
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?.

Oncoimmunology

Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A.
PMID: 28507804
Oncoimmunology. 2017 Mar 03;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.

Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM...

Cite
Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology. 2017;6(4):e1295202doi: 10.1080/2162402X.2017.1295202.
Nijland, M., Veenstra, R. N., Visser, L., Xu, C., Kushekhar, K., van Imhoff, G. W., Kluin, P. M., van den Berg, A., & Diepstra, A. (2017). HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology, 6(4), e1295202. https://doi.org/10.1080/2162402X.2017.1295202
Nijland, Marcel, et al. "HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?." Oncoimmunology vol. 6,4 (2017): e1295202. doi: https://doi.org/10.1080/2162402X.2017.1295202
Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology. 2017 Mar 03;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017. PMID: 28507804; PMCID: PMC5414870.
Copy Download .nbib Format: NLM
Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

Oncoimmunology

van Luijn MM, van den Ancker W, van Ham SM, van de Loosdrecht AA.
PMID: 25964856
Oncoimmunology. 2015 Jan 07;3(12):e941737. doi: 10.4161/21624011.2014.941737. eCollection 2014 Dec.

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of...

Cite
van Luijn MM, van den Ancker W, van Ham SM, et al. Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology. 2015;3(12):e941737doi: 10.4161/21624011.2014.941737.
van Luijn, M. M., van den Ancker, W., van Ham, S. M., & van de Loosdrecht, A. A. (2014). Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology, 3(12), e941737. https://doi.org/10.4161/21624011.2014.941737
van Luijn, Marvin M, et al. "Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia." Oncoimmunology vol. 3,12 (2014): e941737. doi: https://doi.org/10.4161/21624011.2014.941737
van Luijn MM, van den Ancker W, van Ham SM, van de Loosdrecht AA. Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology. 2015 Jan 07;3(12):e941737. doi: 10.4161/21624011.2014.941737. eCollection 2014 Dec. PMID: 25964856; PMCID: PMC4353169.
Copy Download .nbib Format: NLM
Design and Immunological Validation of .

Frontiers in immunology

Neckermann P, Boilesen DR, Willert T, Pertl C, Schrödel S, Thirion C, Asbach B, Holst PJ, Wagner R.
PMID: 34777375
Front Immunol. 2021 Oct 28;12:761214. doi: 10.3389/fimmu.2021.761214. eCollection 2021.

Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high. Thus, an efficient therapy, such as a therapeutic vaccine, is urgently...

Cite
Neckermann P, Boilesen DR, Willert T, et al. Design and Immunological Validation of . Front Immunol. 2021;12:761214doi: 10.3389/fimmu.2021.761214.
Neckermann, P., Boilesen, D. R., Willert, T., Pertl, C., Schrödel, S., Thirion, C., Asbach, B., Holst, P. J., & Wagner, R. (2021). Design and Immunological Validation of . Frontiers in immunology, 12761214. https://doi.org/10.3389/fimmu.2021.761214
Neckermann, Patrick, et al. "Design and Immunological Validation of ." Frontiers in immunology vol. 12 (2021): 761214. doi: https://doi.org/10.3389/fimmu.2021.761214
Neckermann P, Boilesen DR, Willert T, Pertl C, Schrödel S, Thirion C, Asbach B, Holst PJ, Wagner R. Design and Immunological Validation of . Front Immunol. 2021 Oct 28;12:761214. doi: 10.3389/fimmu.2021.761214. eCollection 2021. PMID: 34777375; PMCID: PMC8581358.
Copy Download .nbib Format: NLM
Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy.

Frontiers in chemistry

van Dalen FJ, Bakkum T, van Leeuwen T, Groenewold M, Deu E, Koster AJ, van Kasteren SI, Verdoes M.
PMID: 33644004
Front Chem. 2021 Feb 08;8:628433. doi: 10.3389/fchem.2020.628433. eCollection 2020.

Cathepsin S is a lysosomal cysteine protease highly expressed in immune cells such as dendritic cells, B cells and macrophages. Its functions include extracellular matrix breakdown and cleavage of cell adhesion molecules to facilitate immune cell motility, as well...

Cite
van Dalen FJ, Bakkum T, van Leeuwen T, et al. Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy. Front Chem. 2021;8:628433doi: 10.3389/fchem.2020.628433.
van Dalen, F. J., Bakkum, T., van Leeuwen, T., Groenewold, M., Deu, E., Koster, A. J., van Kasteren, S. I., & Verdoes, M. (2020). Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy. Frontiers in chemistry, 8628433. https://doi.org/10.3389/fchem.2020.628433
van Dalen, Floris J, et al. "Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy." Frontiers in chemistry vol. 8 (2020): 628433. doi: https://doi.org/10.3389/fchem.2020.628433
van Dalen FJ, Bakkum T, van Leeuwen T, Groenewold M, Deu E, Koster AJ, van Kasteren SI, Verdoes M. Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy. Front Chem. 2021 Feb 08;8:628433. doi: 10.3389/fchem.2020.628433. eCollection 2020. PMID: 33644004; PMCID: PMC7903248.
Copy Download .nbib Format: NLM
Characterization of MHC Class II Compartments by Immunoelectron Microscopy.

Methods (San Diego, Calif.)

Kleijmeer MJ, Raposo G, Geuze HJ.
PMID: 8812668
Methods. 1996 Oct;10(2):191-207. doi: 10.1006/meth.1996.0095.

At present the best way to determine the precise intracellular localization of proteins, in a potentially semiquantitative way, is the combination of ultrathin cryosectioning and immunogold labeling. This paper focuses on the intracellular localization of MHC class II molecules,...

Cite
Kleijmeer MJ, Raposo G, Geuze HJ. Characterization of MHC Class II Compartments by Immunoelectron Microscopy. Methods. 1996;10(2):191-207doi: 10.1006/meth.1996.0095.
Kleijmeer, M. J., Raposo, G., & Geuze, H. J. (1996). Characterization of MHC Class II Compartments by Immunoelectron Microscopy. Methods (San Diego, Calif.), 10(2), 191-207. https://doi.org/10.1006/meth.1996.0095
Kleijmeer, et al. "Characterization of MHC Class II Compartments by Immunoelectron Microscopy." Methods (San Diego, Calif.) vol. 10,2 (1996): 191-207. doi: https://doi.org/10.1006/meth.1996.0095
Kleijmeer MJ, Raposo G, Geuze HJ. Characterization of MHC Class II Compartments by Immunoelectron Microscopy. Methods. 1996 Oct;10(2):191-207. doi: 10.1006/meth.1996.0095. PMID: 8812668.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries